GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
- Conditions
- Interventions
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2010-01-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 105
- Registration Number
- NCT01055847
Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 64
- Registration Number
- NCT01054729
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Alamo Medical Research Center, San Antonio, Texas, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)
- Conditions
- Interventions
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01025713
- Locations
- 🇦🇺
Nucleus Network, Ltd., Melbourne, Victoria, Australia
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2010-03-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT00999531
- Locations
- 🇦🇺
Nucleus Network, Ltd., Melbourne, Victoria, Australia
Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
- Conditions
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00989807
- Locations
- 🇨🇦
University of Calgary, Adult CF Clinic, Calgary, Alberta, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 15
- Registration Number
- NCT00951522
- Locations
- 🇦🇺
Nucleus Network, Ltd., Melbourne, Victoria, Australia
Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT00936715
Stress Echocardiography Study With Regadenoson
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2014-01-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 22
- Registration Number
- NCT00907764
- Locations
- 🇬🇧
Northwick Park Hospital, Harrow, United Kingdom
Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
- Conditions
- Interventions
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 85
- Registration Number
- NCT00892437
- Locations
- 🇺🇸
Health for Life Clinic, PLLC, Little Rock, Arkansas, United States
🇺🇸Therapeutic Concepts, P.A., Houston, Texas, United States
🇺🇸AIDS Healthcare Foundation-Research Center, Beverly Hills, California, United States
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT00879229
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇦🇹Medizinische Universität Graz, Graz, Austria
🇦🇹Universitatsklinikum Innsbruck, Innsbruck, Austria